TGTX TG Therapeutics Dashboard

TG Therapeutics, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1101, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in New York, NY.

Company profile

Ticker

TGTX

Exchange

NASDAQ

Website

www.tgtherapeutics.com/

CEO

Michael Weiss

Incorporated

Delaware

Location

New York

Fiscal year end

Dec 31

Sector

Manufacturing > Pharmaceutical Preparation Manufacturing

Industry (SIC)

Pharmaceutical Preparations

Pfizer • Merck & Co • Allergan • Johnson & Johnson • Abbott Laboratories • Teva- Pharmaceutical Industries • Viatris • Bristol-Myers Squibb • Lilly(Eli) & Co • Warner Chilcott ...

Former names

ATLANTIC PHARMACEUTICALS INC, ATLANTIC TECHNOLOGY VENTURES INC, MANHATTAN PHARMACEUTICALS INC

SEC CIK

0001001316

Corporate docs

Articles of Incorporation & Bylaws

IRS number

363898269

TGTX stock data

S&P 500

1M 1Y 2Y 5Y

News

Pro users get this 30m faster

The Week Ahead In Biotech (April 11-17): Avenue Therapeutics FDA Decision and Conference Presentations In The Spotlight

10 Apr 21

Contrary to the strength in the broader market, biotech stocks ended the week ending April 9 lower. The weakness partly reflected a preference for risky bets at the expense of defensives such as healthcare stocks.

TG Therapeutics Highlights Publication OF Results From UNITY-NHL Phase 2b Trial Evaluating Umbralisib Monotherapy In Patients With Relapsed Or Refractory Indolent Non-Hodgkin Lymphoma In Journal Of Clinical Oncology

9 Mar 21

NEW YORK, March 09, 2021 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ:TGTX) today announced the publication of results from the UNITY-NHL Phase 2b trial evaluating UKONIQ™ (umbralisib), the Company's

TG Therapeutics Says To Presents Results From ULTIMATE I & II Phase 3 Trials Evaluating Ublituximab In Multiple Sclerosis At Upcoming American Academy Of Neurology Annual Meeting

4 Mar 21

TG Therapeutics to Present Results from the ULTIMATE I & II Phase 3 Trials Evaluating Ublituximab in Multiple Sclerosis at the Upcoming American Academy of Neurology 73rd Annual Meeting NEW YORK, March 04, 2021

TG Therapeutics Q4 EPS $(0.71) Misses $(0.58) Estimate, Sales $38.00K Inline

2 Mar 21

Earnings Scheduled For March 2, 2021

2 Mar 21

Press releases

Pro users get this 30m faster

TG Therapeutics Completes Rolling Submission of Biologics License Application to the U.S. Food and Drug Administration for Ublituximab in Combination with UKONIQ™(umbralisib) as a Treatment for Patients with Chronic Lymphocytic Leukemia

29 Mar 21

NEW YORK, March 29, 2021 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ:TGTX), today announced the completion of the rolling submission of a Biologics License Application (BLA) to the U.S. Food and Drug

TG Therapeutics Announces Publication of Results from the UNITY-NHL Phase 2b Trial Evaluating Umbralisib Monotherapy in Patients with Relapsed or Refractory Indolent non-Hodgkin Lymphoma in the Journal of Clinical Oncology

9 Mar 21

TG Therapeutics to Present Results from the ULTIMATE I & II Phase 3 Trials Evaluating Ublituximab in Multiple Sclerosis at the Upcoming American Academy of Neurology 73rd Annual Meeting

4 Mar 21

NEW YORK, March 04, 2021 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ:TGTX), today announced that results of the ULTIMATE I & II Phase 3 trials evaluating ublituximab, the Company's novel, glycoengineered

TG Therapeutics to Present at the H.C. Wainwright Global Life Sciences Conference

4 Mar 21

TG Therapeutics Provides Business Update and Reports Fourth Quarter and Year-End 2020 Financial Results

2 Mar 21

Investment data

Data from SEC filings

Securities sold

Number of investors

Calendar

1 Mar 21

11 Apr 21

31 Dec 21

Financial summary

Financial statements Chart TGTX financial data

Quarter (USD)	Dec 20	Sep 20	Jun 20	Mar 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 20	Dec 19	Dec 18	Dec 17
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from company earnings reports.

Cash burn rate (estimated)	Burn method: Change in cash		Burn method: Operating income/loss		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	554.7M	554.7M	554.7M	554.7M	554.7M	554.7M
Cash burn (monthly)	(positive/no burn)	(positive/no burn)	28.93M	22.8M	17.34M	17.88M
Cash used (since last report)	n/a	n/a	97.63M	76.95M	58.53M	60.33M
Cash remaining	n/a	n/a	457.07M	477.75M	496.17M	494.37M
Runway (months of cash)	n/a	n/a	15.8	21.0	28.6	27.7

Beta Read what these cash burn values mean

Recent insider trades

TGTX insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
30 Dec 20	Power Sean A	COMMON STOCK	Grant	Aquire A	No	No	0	20,000	0	653,338
28 Dec 20	Weiss Michael S	COMMON STOCK	Gift	Dispose G	Yes	No	0	655	0	13,068,082
28 Dec 20	Weiss Michael S	COMMON STOCK	Gift	Dispose G	No	No	0	1,000	0	13,068,737
22 Dec 20	Weiss Michael S	COMMON STOCK	Gift	Dispose G	No	No	0	200	0	13,069,737
21 Dec 20	Power Sean A	COMMON STOCK	Gift	Dispose G	No	No	0	7,000	0	629,438
15 Dec 20	Weiss Michael S	COMMON STOCK	Gift	Dispose G	No	No	0	200	0	13,069,937
15 Dec 20	Weiss Michael S	COMMON STOCK	Gift	Dispose G	No	No	0	1,700	0	13,070,137
15 Dec 20	Weiss Michael S	COMMON STOCK	Gift	Dispose G	No	No	0	834,877	0	13,071,837
10 Dec 20	Echelard Yann	COMMON STOCK	Sell	Dispose S	No	No	40.05	30,000	1.2M	129,116
9 Oct 20	Power Sean A	COMMON STOCK	Gift	Dispose G	No	No	0	125,000	0	636,438

Data from 3, 4 and 5 filings. Stock values as filed, not updated for current price.

Institutional ownership Q4 2020

TGTX institutional ownership history Ownership history

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

71.1% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	250	179	+39.7%
Opened positions	87	31	+180.6%
Closed positions	16	25	-36.0%
Increased positions	76	72	+5.6%
Reduced positions	57	50	+14.0%

13F shares	Current	Prev Q	Change
Total value	5.8B	3.28B	+76.6%
Total shares	99.9M	86.39M	+15.6%
Total puts	1.02M	929.3K	+9.5%
Total calls	1.55M	1.17M	+32.7%
Total put/call ratio	0.7	0.8	-17.5%

Largest owners	Shares	Value	Change
FMR	14.83M	$771.31M	+35.3%
Vanguard	10.97M	$570.7M	+46.5%
Ra Capital Management	8.69M	$451.82M	-1.6%
BLK Blackrock	8.56M	$445.1M	+11.3%
Wellington Management	4.92M	$255.83M	+48.7%
Lord, Abbett & Co.	4.44M	$230.99M	-11.2%
Alkeon Capital Management	4.08M	$212.15M	+47.0%
STT State Street	3.71M	$193.14M	-9.6%
Maverick Capital	3.2M	$166.57M	-27.1%
IVZ Invesco	1.78M	$92.66M	+68.0%

Largest transactions	Shares	Bought/sold	Change
FMR	14.83M	+3.87M	+35.3%
Vanguard	10.97M	+3.48M	+46.5%
Wellington Management	4.92M	+1.61M	+48.7%
Great Point Partners	0	-1.6M	EXIT
TROW T. Rowe Price	1.4M	+1.35M	+2646.3%
Alkeon Capital Management	4.08M	+1.3M	+47.0%
Norges Bank	1.28M	+1.28M	NEW
Maverick Capital	3.2M	-1.19M	-27.1%
Logos Global Management	850K	-900K	-51.4%
BLK Blackrock	8.56M	+871.57K	+11.3%

Data from 13F filings. Stock values as filed, not updated for current price. Long positions only.

Financial report summary

Competition

Celgene • Astrazeneca • Roche • Viracta Therapeutics • Curis • Novartis • Stemline Therapeutics • Constellation Pharmaceuticals • Calithera Biosciences • Karyopharm Therapeutics

Management Discussion

License Revenue. License revenue was approximately $152,000 for each of the years ended December 31, 2020 and 2019. License revenue is related to the amortization of an upfront payment of $2.0 million associated with our license agreement with Ildong. The upfront payment from Ildong will be recognized as license revenue on a straight-line basis through December 2025, which represents the estimated period over which we will have certain ongoing responsibilities under the sublicense agreement.
Noncash Stock Expense Associated with In-Licensing Agreement (Research and Development). Noncash stock expense associated with in-licensing agreement (research and development) amounted to zero for the year ended December 31, 2020, as compared to $0.1 million during the comparable period in 2019.
Noncash Compensation Expense (Research and Development). Noncash compensation expense (research and development) related to equity incentive grants totaled $14.0 million for the year ended December 31, 2020, as compared to $5.8 million during the comparable period in 2019. The increase in noncash compensation expense was primarily due to an increase in research and development personnel and a higher stock price during the year ended December 31, 2020.

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. junior Avg

New words: abnormal, abnormally, abundance, advocacy, age, AKS, ALT, altogether, argument, AST, atrial, backlog, barrier, behaving, bidding, Biden, biology, bleeding, bona, budgetary, built, causality, caution, CCPA, chose, cleanup, color, CPRA, cultivate, cybersecurity, debilitating, deferral, depression, destruction, detention, disallowed, discriminate, discrimination, disgorgement, distancing, domestic, driven, DSCSA, Dysregulation, ECs, EEA, elevated, epidemic, Epizyme, exacerbated, explicitly, fallout, fastest, feel, fibrillation, fide, Florida, footprint, foster, FTC, FTCA, fulfill, fulfilling, garner, GDPR, gender, globe, hear, heightened, heightening, home, hypertension, IA, immunological, immunosuppressive, inclusion, inclusive, inconsistent, indeterminate, infection, Justice, Lanham, leakage, learning, legislature, legitimize, leukopenia, marital, Mexico, mount, navigate, Nevada, NOL, notification, nurse, ODD, oncoprotein, opportunistic, opt, organizational, orientation, outbreak, pandemic, paramount, payroll, pendency, persist, pharmacovigilance, phosphoinositide, PHS, pioneering, postmarketing, pre, preapproval, pride, prioritization, QD, quarantine, rash, recession, redisclosure, registry, reinterpreted, religion, reluctance, remote, remotely, rescission, resume, Riley, Russia, salary, sexual, Shield, shipping, skilled, slowdown, slowest, sophisticated, sought, spread, spreading, Squibb, strictly, strive, stronger, subsidized, sugar, tazemetostat, thrombocytopenia, tracing, transport, travel, UKONIQ, UKONIQTM, umbrella, uMRD, underinsured, unimpeded, UNITY, unlawful, untrue, vaccination, variant, verification, veteran, virtually, Waldenstrom, weigh, wholesale, workplace, Wuhan

Removed: AACR, aberrant, Advisor, apportioned, ASCO, assume, begun, Belgium, Biogen, blocked, Cannon, capitalization, carfilzomib, certify, Chicago, Columbia, condensed, confusion, content, coupled, cytotoxic, DCD, death, deliver, demonstration, deplete, depleting, Dr, enabling, estimation, exceeding, exert, falling, Fc, forfeit, Genentech, House, Howard, Idec, identity, IL, inappropriately, inspect, intending, likewise, liver, marketable, match, Modernization, myeloma, nanomolar, Nashville, NCE, negotiating, NK, nondeductible, notably, object, ordered, ordinarily, origin, oversee, Owen, packaged, PCD, poverty, predominantly, Presbyterian, presidential, proteasome, proving, ratably, recognition, referenced, reflected, removing, reproduced, Sarah, session, show, silence, Simultaneously, Skip, strongly, substitute, supplemental, surface, synergy, TN, today, unproven, vested, waive

From filing 10-K 2020 FY